AI Daily: OpenAI argues to keep countersuit against Musk

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly:

COUNTERSUIT: Microsoft (MSFT)-backed OpenAI is arguing to keep its countersuit against Tesla (TSLA) CEO Elon Musk in the trial over for-profit shift, Reuters reports. OpenAI says the Tesla CEO’s motion to dismiss the ChatGPT maker’s claims has “no grounding in facts,” and that its countersuit should be included in the expedited trial, rather than put on hold.

AI PLATFORM GPTBOTS.AI: Aurora Mobile (JG) announced the integration of newly updated DeepSeek-R1-0528-a groundbreaking open-source reasoning AI model that rivals proprietary giants like OpenAI’s o3 and Google’s (GOOG, GOOGL) Gemini 2.5 Pro-into its leading enterprise-grade AI platform GPTBots.ai. This significant update, released by DeepSeek, brings enhanced reasoning capabilities and developer-friendly features, further empowering GPTBots.ai to deliver cutting-edge AI solutions to enterprises worldwide. The DeepSeek-R1-0528 model brings substantial advancements in reasoning capabilities, achieving notable benchmark improvements such as AIME 2025 accuracy rising from 70% to 87.5% and LiveCodeBench coding performance increasing from 63.5% to 73.3%. These enhancements empower GPTBots.ai users to tackle complex tasks in domains like math, science, business, and programming with greater precision and efficiency. Additionally, the model’s reduced hallucination rate, along with support for JSON output and function calling, ensures seamless integration into business workflows, delivering reliable and consistent results. These improvements align perfectly with the mission of GPTBots.ai to provide secure, scalable, and enterprise-ready AI solutions.

AI INITIATIVE: Tevogen (TVGN) provided stockholders a detailed overview of its artificial intelligence initiative, Tevogen.AI, aimed at integrating advanced machine learning into its ExacTcell technology to enhance target identification and preclinical processes. Tevogen.AI currently has two proprietary technologies, PredicTcell and AdapTcell, both with patents pending. The company also highlighted strategic partnerships with Microsoft, providing AI expertise and cloud computing infrastructure, and Databricks, supplying data engineering and analytics capabilities. Tevogen plans to expand its headquarters for the Tevogen.AI team.